Out of 135 brain tumor samples tested, 28 (20.7%) had one clinically relevant variant, 11 (8.1%) had a BRAF Val600Glu variant, 14 (10.3%) had an IDH1 Arg132 variant, and 3 (2.2%) had an IDH2 Arg172 variant (Supplementary File 5). This evidence concerns the gene IDH2 and brain neoplasm.